Thanks, ROCKY. I understand that one of the patient screening impediments, if you will, is the eye sight parameters required/initial study approved, by the FDA.
Are you observing anywhere a change in those parameters, or does that, if meaningful for the clinicals, mean going back to step one and study re-design approval with the FDA?
Thanks.